-
The first domestically produced new crown neutralizing antibody combination therapy is coming!
Time of Update: 2021-10-21
> (EUA) application to the US Food and Drug Administration (FDA) for its SARS-CoV-2 combination therapy BRII-196/BRII-198<span
-
Revealed: 31 drugs or therapies around the world won the Nobel Prize. What is the next Nobel Prize for "New Drug Research and Development"?
Time of Update: 2021-10-21
For example, the 2019 Nobel Prize in Physiology or Medicine is awarded to scientists who have made important contributions in the field of oxygen sensing pathway research .
-
Notice on Publicly Soliciting Opinions on the "Technical Guidelines for the Design of Clinical Trials of Long-acting Granulocyte Colony Stimulating Factor Preventing Infection after Chemotherapy (Draft for Solicitation of Comments)"
Time of Update: 2021-10-21
docx "Long-acting Granulocyte Colony Stimulating Factor Clinical Trial Design Technical Guidelines for the Prevention of Infection after Chemotherapy (Draft for Solicitation of Comments)" feedback form for soliciting opinions.
-
Exploration and Thoughts on the Price Formation Mechanism of Innovative Drugs
Time of Update: 2021-10-21
Through national talks, the price reduction of innovative drugs to achieve medical insurance access and speed up the commercialization process is of great significance for improving accessibility .
-
Benchmark Medical/Twist Bioscience pan-cancer methylation products are launched globally
Time of Update: 2021-10-21
from https:// The pan-cancer methylation product jointly developed by Benchmark Medical and Twist Bioscience is launched globally.
-
The "Giant Whale" is swinging its tail and the industry is turning-where will the "new golden decade" of China's innovative drugs go?
Time of Update: 2021-10-21
>. > It is true that in the current pharmaceutical industry in China, there are only a handful of companies that can meet the above three conditions, among which are the “big factories” worthy of the name and no one
-
Class 1 new Chinese medicines welcome the blowout, Renfu, Kangyuan...12 blockbuster sprints are on the market!
Time of Update: 2021-10-21
disease medications are still very popular. Four Class 1 new drugs have been approved for clinical use. Currently Tasly’s T89 (Compound Danshen Dripping Pills) The indications for the prevention and treatment of acute altitude
-
Encourage the R&D and production of children's medications through multiple measures-to meet medication needs and ensure medication safety
Time of Update: 2021-10-21
by a pharmaceutical company in Hunan were approved for marketing, and children with hepatitis B have special drugs . > "Take medicine by breaking, and dosage by guessing <br
-
BeiGene Baiyueze® (Zebutinib) was approved for the treatment of mantle cell lymphoma
Time of Update: 2021-10-21
On October 11, BeiGene announced that Baiyueze® (Zebutinib) has been approved in Australia for the treatment of adult patients with mantle cell lymphoma (MCL) who have previously received at least one therapy .
-
Hebo Pharma FcRn antibody enters the third clinical phase!
Time of Update: 2021-10-21
>Chinese FcRn antibody goes further Not long ago, Hebo Pharma announced that its fully human anti-FcRn antibody bartolizumab (HBM9161) for systemic myasthenia gravis (MG) clinical trial has completed the first
-
Today, Heyu Pharmaceutical is officially listed on the Hong Kong Stock Exchange
Time of Update: 2021-10-21
>. Since its establishment, the company has established a pipeline of 14 drug candidates focused on oncology, including 5 drug candidates in the clinical stage <span
-
New opportunities for innovative drug research and development in September 2021
Time of Update: 2021-10-21
TNK1 inhibitor On September 9, 2021, researchers from Brigham Young University and Sumitomo Dainippon Pharma reported on the new anti-cancer target TNK1 on Nat Commun, and developed a small molecule inhibitor TP-5801 .
-
Over 450 million US dollars: Hausen introduces siRNA therapy for liver disease
Time of Update: 2021-10-21
As part of the cooperation agreement, the two companies will use OliX Pharmaceuticals’ GalNAc-asiRNA platform and Hansen Pharmaceuticals’ strong R&D, production and commercialization capabilities in China to develop multiple hepatocyte-targeted products, involving Areas include cardiovascular, metabolic and other indications .
-
AstraZeneca Global R&D China Center officially opened
Time of Update: 2021-10-21
On October 11, AstraZeneca, the world's leading multinational pharmaceutical company, announced the official opening of its Global R&D China Center in Jing'an District, Shanghai .
-
[Authoritative release] National Health Commission and Zhejiang Provincial Government jointly create a provincial demonstration of high-quality development
Time of Update: 2021-10-21
and technology innovation platform, incorporate it into the national medical innovation system, cooperate in the implementation of a number of major scientific research projects, and speed up the resolution of the neck problem in the medical field </span
-
8 pharmaceutical companies!
Time of Update: 2021-10-21
>. The company has been profitable for the past three years, and the overall financial situation is sound. Sales revenue and total profit are showing a steady upward trend, and cash flow is sufficient </span
-
The development of commercial insurance needs to grasp the "3 degrees"
Time of Update: 2021-10-21
On the basis of providing basic medical insurance services, how to better encourage and support the development of commercial health insurance is a major issue for the Healthy China strategy and the construction of China's multi-level medical security system .
-
Groundbreaking research on the mechanism of type 1 diabetes therapy yields positive results, GK agonist TTP399 does not increase the risk of ketoacidosis
Time of Update: 2021-10-21
at the request of the FDA to prove that TTP399 would not cause the production of keto acids and secondary DKA . > TTP399 is a selective glucokinase agonist. With the results
-
"SPAC mode" cited the CSRC's high attention!
Time of Update: 2021-10-21
>It plans to raise US$300 million in Hong Kong for the development, production and commercialization of related vaccines . > As of now, 23 medical and health companies have been listed
-
New drug for super rare diseases: FDA approves Rethymic to treat congenital athymic children
Time of Update: 2021-10-21
Recently, the US Food and Drug Administration (FDA) approved Enzyvant Sciences' Rethymic (Allogeneic Treated Thymus Tissue-agdc) for the treatment of congenital athymic children .
